ALG12-congenital disorder of glycosylation
Overview
ALG12-congential disorder of glycosylation (ALG12-CDG) is a rare, inherited multi-system condition caused by mutations in the ALG12 Gene, leading to intellectual disability, weak muscle tone, and immune issues
Symptoms
Growth and Neurological Signs
Failure to thrive: Feeding difficulties and trouble gaining weight.
Hypotonia: Weak or low muscle tone.
Developmental delay: Delayed motor skills and moderate-to-severe intellectual disability.
Seizures: Developing in some affected individuals.Microcephaly: Progressive small head size.
Physical and Facial Features
Facial dysmorphism: Prominent nasal bridge or forehead, epicanthal eye folds, and abnormally shaped or large ears.
Skeletal abnormalities: Poor bone development and abnormal bone ossification.
Genital abnormalities: Micropenis and undescended testes (cryptorchidism) in males.
Immune and Other Complications
Low antibodies: Hypogammaglobulinemia (reduced immunoglobulin G/IgG levels) leading to frequent respiratory and other infections.
Blood and heart issues: Abnormal blood clotting/coagulation factors and occasional heart muscle weakness.
Hearing and vision: Sensorineural hearing loss and crossed eyes (strabismus) in some cases.
Causes
Gene Mutations: Pathogenic variants or deletions occur in the ALG12 gene located on chromosome 22q13.33.
Enzyme Deficiency: The mutation causes a shortage or dysfunction of the mannosyltransferase enzyme encoded by ALG12.
Impaired Glycosylation: The abnormal enzyme fails to properly add mannose sugar molecules to the growing lipid-linked oligosaccharide chain, resulting in incomplete sugar chains and deficient modification of vital proteins and fats needed across multiple body systems
Developmental Impact: Intellectual disability, global developmental delay, and weak muscle tone (hypotonia).
Growth Issues: Failure to thrive, poor growth in infancy, and short stature.
Immune & Blood Complications: Low antibody/immunoglobulin levels (hypogammaglobulinemia) leading to frequent infections, alongside blood-clotting (coagulation) abnormalities
Diagnosis
Initial Screening: Blood tests analyze serum transferrin to check for abnormal N-linked glycan patterns.
Enzyme and Functional Testing: Measuring specific enzyme activity in blood or skin fibroblasts supports the biochemical defect.
Definitive Genetic Testing: Exome sequencing or targeted gene panels confirm pathogenic variants in the ALG12 gene
Neurological: Generalized hypotonia (weak muscle tone), developmental delay, and intellectual disability.
Immunological: Low immunoglobulin (IgG) levels leading to frequent infections.
Physical & Structural: Failure to thrive, microcephaly, distinct facial features, and male genital abnormalities.
Treatment
Developmental support: Physical, occupational, and speech therapy to help with developmental delays and low muscle tone (hypotonia).
Feeding support: Dietary adjustments, specialized high-calorie formulas, or feeding tubes (like a G-tube) to treat failure to thrive and feeding difficulties.
Infection control: Prompt treatment of frequent upper respiratory and other infections, which happen due to low immune globulin levels.
Seizure control: Standard anti-seizure medications prescribed and monitored by a neurologist for patients who experience seizures.Cardiac and skeletal monitoring:
Type of Doctor Department : A medical geneticist (clinical geneticist) or a metabolic specialist (biochemical geneticist)
.jpg)
Comments
Post a Comment